Haematologica· 2026Q1
Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis
- 0citations
- Q1SCImago
- 2026year
Short summary
Maintenance therapy with lenalidomide, thalidomide, or bortezomib after autologous stem cell transplant (ASCT) for multiple myeloma significantly improves overall survival (OS) at 3 years compared to no maintenance, according to a global analysis of 8,269 patients.
AI-generated from the title and abstract; the full text is not read.
Key points
- Maintenance therapy after ASCT for multiple myeloma improves overall survival (OS).
- Lenalidomide maintenance resulted in the highest 3-year OS at 86%.
- Bortezomib (83%) and thalidomide (80%) maintenance also improved OS compared to no maintenance (79%).
- The analysis included 8,269 patients from the WBMT registry, transplanted between 2013-2017.
AI-generated from the title and abstract; the full text is not read.
Abstract
The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marrow Transplantation (WBMT) registry. Overall survival (OS) was evaluated as primary and progression-free survival (PFS), non-relapse mortality and relapse/progression incidence as secondary endpoints. Multivariable 6- month landmark analyses were performed using Cox proportional hazards models including random effect for country. Information was available on 8,269 patients with lenalidomide (n=4,148; 50.2%), thalidomide (n=689; 8.3%) or bortezomib (n=726; 8.8%) as maintenance or no maintenance (n=2,706; 32.7%). In the 6-month landmark analysis, OS at 3 years was higher after maintenance with lenalidomide (86%), with thalidomide (80%) and with bortezomib (83%) as compared to no maintenance (79%, p.
The authors' abstract, as published at the source. Haematologica, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine